A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
Study of Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
Sponsor: GlaxoSmithKline
Enrolling: Male and Female Patients
IRB Number: AAAT0104
U.S. Govt. ID: NCT04246047
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: Belantamab Mafodotin is a new therapy for patients with Multiple Myeloma. The drug works by combining chemotherapy and immunotherapy approach to treat Multiple Myeloma. The drug is a combination of an antibody against a target on plasma cells called BCMA and a chemotherapeutic agent called MMAF. The drug has shown activity in patients with late relapses of Multiple Myeloma. Because of its unique mechanism of action and activity, this trial will test the drug in patients with early relapse to evaluate if the drug in combination with Bortezomib and Dexamethasone will have better outcomes than the current standard of care.
This study is closed
Divaya Bhutani, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you received previous treatment for multiple myeloma? Yes No
Did you have disease progression during or after your treatment? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator